Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 1/2017

01-02-2017 | Review

Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer

Authors: Antonieta Chavez-Gonzalez, Babak Bakhshinejad, Katayoon Pakravan, Monica L. Guzman, Sadegh Babashah

Published in: Cellular Oncology | Issue 1/2017

Login to get access

Abstract

Background

Cancer stem cells (CSCs), also known as tumor-initiating cells (TICs), are characterized by high self-renewal and multi-lineage differentiation capacities. CSCs are thought to play indispensable roles in the initiation, progression and metastasis of many types of cancer. Leukemias are thought to be initiated and maintained by a specific sub-type of CSC, the leukemia stem cell (LSC). An important feature of LSCs is their resistance to standard therapy, which may lead to relapse. Increasing efforts are aimed at developing novel therapeutic strategies that selectively target LSCs, while sparing their normal counterparts and, thus, minimizing adverse treatment-associated side-effects. These LSC targeting therapies aim to eradicate LSCs through affecting mechanisms that control their survival, self-renewal, differentiation, proliferation and cell cycle progression. Some LSC targeting therapies have already been proven successful in pre-clinical studies and they are now being tested in clinical studies, mainly in combination with conventional treatment regimens.

Conclusions

A growing body of evidence indicates that the selective targeting of LSCs represents a promising approach to improve disease outcome. Beyond doubt, the CSC hypothesis has added a new dimension to the area of anticancer research, thereby paving the way for shaping a new trend in cancer therapy.
Appendix
Available only for authorised users
Literature
1.
2.
3.
D.C. Taussig, F. Miraki-Moud, F. Anjos-Afonso, D.J. Pearce, K. Allen, C. Ridler, D. Lillington, H. Oakervee, J. Cavenagh, S.G. Agrawal, T.A. Lister, J.G. Gribben, D. Bonnet, Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112, 568–575 (2008). doi:10.​1182/​blood-2007-10-118331 CrossRefPubMed
4.
D.C. Taussig, J. Vargaftig, F. Miraki-Moud, E. Griessinger, K. Sharrock, T. Luke, D. Lillington, H. Oakervee, J. Cavenagh, S.G. Agrawal, T.A. Lister, J.G. Gribben, D. Bonnet, Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 115, 1976–1984 (2010). doi:10.​1182/​blood-2009-02-206565 CrossRefPubMedPubMedCentral
5.
S. Aref, O. Salama, Y. Al-Tonbary, M. Fouda, A. Menessy, M. El-Sherbiny, L and E selectins in acute myeloid leukemia: expression, clinical relevance and relation to patient outcome. Hematology 7, 83–87 (2002). doi:10.​1080/​1024533029002857​9 CrossRefPubMed
6.
7.
F. Ishikawa, S. Yoshida, Y. Saito, A. Hijikata, H. Kitamura, S. Tanaka, R. Nakamura, T. Tanaka, H. Tomiyama, N. Saito, M. Fukata, T. Miyamoto, B. Lyons, K. Ohshima, N. Uchida, S. Taniguchi, O. Ohara, K. Akashi, M. Harada, L.D. Shultz, Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 25, 1315–1321 (2007). doi:10.​1038/​nbt1350 CrossRefPubMed
8.
T. Holyoake, X. Jiang, C. Eaves, A. Eaves, Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94, 2056–2064 (1999)PubMed
9.
C. Zhao, A. Chen, C.H. Jamieson, M. Fereshteh, A. Abrahamsson, J. Blum, H.Y. Kwon, J. Kim, J.P. Chute, D. Rizzieri, M. Munchhof, T. VanArsdale, P.A. Beachy, T. Reya, Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776–779 (2009). doi:10.​1038/​nature07737 CrossRefPubMedPubMedCentral
10.
11.
C.T. Jordan, D. Upchurch, S.J. Szilvassy, M.L. Guzman, D.S. Howard, A.L. Pettigrew, T. Meyerrose, R. Rossi, B. Grimes, D.A. Rizzieri, S.M. Luger, G.L. Phillips, The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777–1784 (2000)CrossRefPubMed
12.
13.
14.
Y. Kikushige, T. Shima, S. Takayanagi, S. Urata, T. Miyamoto, H. Iwasaki, K. Takenaka, T. Teshima, T. Tanaka, Y. Inagaki, K. Akashi, TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 7, 708–717 (2010). doi:10.​1016/​j.​stem.​2010.​11.​014 CrossRefPubMed
15.
M.P. Scolnik, R. Morilla, M.M. de Bracco, D. Catovsky, E. Matutes, CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease. Leuk. Res. 26, 615–619 (2002)CrossRefPubMed
16.
A. Chavez-Gonzalez, E. Dorantes-Acosta, D. Moreno-Lorenzana, A. Alvarado-Moreno, L. Arriaga-Pizano, H. Mayani, Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia. Arch. Med. Res. 45, 343–350 (2014). doi:10.​1016/​j.​arcmed.​2014.​04.​001 CrossRefPubMed
17.
J.M. Gerber, B.D. Smith, B. Ngwang, H. Zhang, M.S. Vala, L. Morsberger, S. Galkin, M.I. Collector, B. Perkins, M.J. Levis, C.A. Griffin, S.J. Sharkis, M.J. Borowitz, J.E. Karp, R.J. Jones, A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 119, 3571–3577 (2012). doi:10.​1182/​blood-2011-06-364182 CrossRefPubMedPubMedCentral
18.
M. Jaras, P. Johnels, N. Hansen, H. Agerstam, P. Tsapogas, M. Rissler, C. Lassen, T. Olofsson, O.W. Bjerrum, J. Richter, T. Fioretos, Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc. Natl. Acad. Sci. U. S. A. 107, 16280–16285 (2010). doi:10.​1073/​pnas.​1004408107 CrossRefPubMedPubMedCentral
19.
H. Herrmann, I. Sadovnik, S. Cerny-Reiterer, T. Rulicke, G. Stefanzl, M. Willmann, G. Hoermann, M. Bilban, K. Blatt, S. Herndlhofer, M. Mayerhofer, B. Streubel, W.R. Sperr, T.L. Holyoake, C. Mannhalter, P. Valent, Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood 123, 3951–3962 (2014). doi:10.​1182/​blood-2013-10-536078 CrossRefPubMed
20.
M.E. Chamuleau, G.J. Ossenkoppele, A. van Rhenen, L. van Dreunen, S.M. Jirka, A. Zevenbergen, G.J. Schuurhuis, A.A. van de Loosdrecht, High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2. Leuk. Res. 35, 741–749 (2011). doi:10.​1016/​j.​leukres.​2010.​12.​032 CrossRefPubMed
21.
M. Terwijn, N. Feller, A. van Rhenen, A. Kelder, G. Westra, S. Zweegman, G. Ossenkoppele, G.J. Schuurhuis, Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. Eur. J. Cancer 45, 1692–1699 (2009). doi:10.​1016/​j.​ejca.​2009.​02.​021 CrossRefPubMed
22.
M. Terwijn, W. Zeijlemaker, A. Kelder, A.P. Rutten, A.N. Snel, W.J. Scholten, T. Pabst, G. Verhoef, B. Lowenberg, S. Zweegman, G.J. Ossenkoppele, G.J. Schuurhuis, Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One 9, e107587 (2014). doi:10.​1371/​journal.​pone.​0107587 CrossRefPubMedPubMedCentral
23.
A.V. Krivtsov, D. Twomey, Z. Feng, M.C. Stubbs, Y. Wang, J. Faber, J.E. Levine, J. Wang, W.C. Hahn, D.G. Gilliland, T.R. Golub, S.A. Armstrong, Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818–822 (2006). doi:10.​1038/​nature04980 CrossRefPubMed
24.
L.I. Shlush, S. Zandi, A. Mitchell, W.C. Chen, J.M. Brandwein, V. Gupta, J.A. Kennedy, A.D. Schimmer, A.C. Schuh, K.W. Yee, J.L. McLeod, M. Doedens, J.J. Medeiros, R. Marke, H.J. Kim, K. Lee, J.D. McPherson, T.J. Hudson, A.M. Brown, F. Yousif, Q.M. Trinh, L.D. Stein, M.D. Minden, J.C. Wang, J.E. Dick, Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328–333 (2014). doi:10.​1038/​nature13038 CrossRefPubMedPubMedCentral
25.
26.
S. Babashah, Cancer stem cells: emerging concepts and future perspectives in translational oncology (Springer International Publishing, Switzerland, 2015)CrossRef
27.
P.R. Hamann, L.M. Hinman, I. Hollander, C.F. Beyer, D. Lindh, R. Holcomb, W. Hallett, H.R. Tsou, J. Upeslacis, D. Shochat, A. Mountain, D.A. Flowers, I. Bernstein, Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13, 47–58 (2002)CrossRefPubMed
28.
29.
A. Dutour, V. Marin, I. Pizzitola, S. Valsesia-Wittmann, D. Lee, E. Yvon, H. Finney, A. Lawson, M. Brenner, A. Biondi, E. Biagi, R. Rousseau, In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. Adv. Hematol. 2012, 683065 (2012). doi:10.​1155/​2012/​683065 CrossRefPubMedPubMedCentral
30.
I. Pizzitola, V. Agostoni, E. Cribioli, M. Pule, R. Rousseau, H. Finney, A. Lawson, A. Biondi, E. Biagi, V. Marin, In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy. J. Immunother. 34, 469–479 (2011). doi:10.​1097/​CJI.​0b013e31821e763b​ CrossRefPubMed
31.
M. Feuring-Buske, A.E. Frankel, R.L. Alexander, B. Gerhard, D.E. Hogge, A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res. 62, 1730–1736 (2002)PubMed
32.
33.
L. Jin, E.M. Lee, H.S. Ramshaw, S.J. Busfield, A.G. Peoppl, L. Wilkinson, M.A. Guthridge, D. Thomas, E.F. Barry, A. Boyd, D.P. Gearing, G. Vairo, A.F. Lopez, J.E. Dick, R.B. Lock, Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5, 31–42 (2009). doi:10.​1016/​j.​stem.​2009.​04.​018 CrossRefPubMed
34.
S.J. Busfield, M. Biondo, M. Wong, H.S. Ramshaw, E.M. Lee, S. Ghosh, H. Braley, C. Panousis, A.W. Roberts, S.Z. He, D. Thomas, L. Fabri, G. Vairo, R.B. Lock, A.F. Lopez, A.D. Nash, Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia 28, 2213–2221 (2014). doi:10.​1038/​leu.​2014.​128 CrossRefPubMed
35.
I. Pizzitola, F. Anjos-Afonso, K. Rouault-Pierre, F. Lassailly, S. Tettamanti, O. Spinelli, A. Biondi, E. Biagi, D. Bonnet, Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 28, 1596–1605 (2014). doi:10.​1038/​leu.​2014.​62 CrossRefPubMed
36.
S. Gill, S.K. Tasian, M. Ruella, O. Shestova, Y. Li, D.L. Porter, M. Carroll, G. Danet-Desnoyers, J. Scholler, S.A. Grupp, C.H. June, M. Kalos, Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 123, 2343–2354 (2014). doi:10.​1182/​blood-2013-09-529537 CrossRefPubMedPubMedCentral
37.
Z. Gadhoum, J. Delaunay, E. Maquarre, L. Durand, V. Lancereaux, J. Qi, J. Robert-Lezenes, C. Chomienne, F. Smadja-Joffe, The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leuk. Lymphoma 45, 1501–1510 (2004). doi:10.​1080/​1042819042000206​687 CrossRefPubMed
38.
39.
40.
J.L. Berkowitz, J.E. Janik, D.M. Stewart, E.S. Jaffe, M. Stetler-Stevenson, J.H. Shih, T.A. Fleisher, M. Turner, N.E. Urquhart, G.H. Wharfe, W.D. Figg, C.J. Peer, C.K. Goldman, T.A. Waldmann, J.C. Morris, Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clin. Immunol. 155, 176–187 (2014). doi:10.​1016/​j.​clim.​2014.​09.​012 CrossRefPubMedPubMedCentral
41.
J. Cerny, H. Yu, M. Ramanathan, G.D. Raffel, W.V. Walsh, N. Fortier, L. Shanahan, E. O’Rourke, J. Bednarik, B. Barton, A. Kroll-Desrosiers, S. Hao, B. Woda, L. Hutchinson, A.M. Evens, A.G. Rosmarin, R. Nath, Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML). Br. J. Haematol. 160, 262–266 (2013). doi:10.​1111/​bjh.​12109 CrossRefPubMed
42.
G.J.R. J. N. Allan, E. J. Feldman, J. M. Scandura, E. K. Ritchie, L. Lam, W. Xie, H-T Hsu, D. C. Hassane, M. L. Guzman, In 56th ASH Annual Meeting and Exposition, (San Francisco, CA) (2014)
43.
Z. Guo, A. Wang, W. Zhang, M. Levit, Q. Gao, C. Barberis, M. Tabart, J. Zhang, D. Hoffmann, D. Wiederschain, J. Rocnik, F. Sun, J. Murtie, C. Lengauer, S. Gross, B. Zhang, H. Cheng, V. Patel, L. Schio, F. Adrian, M. Dorsch, C. Garcia-Echeverria, S.M. Huang, PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene. Blood 124, 1777–1789 (2014). doi:10.​1182/​blood-2014-01-551234 CrossRefPubMed
44.
45.
H. Lu, Q. Zhou, V. Deshmukh, H. Phull, J. Ma, V. Tardif, R.R. Naik, C. Bouvard, Y. Zhang, S. Choi, B.R. Lawson, S. Zhu, C.H. Kim, P.G. Schultz, Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angew. Chem. Int. Ed. Engl. 53, 9841–9845 (2014). doi:10.​1002/​anie.​201405353 CrossRefPubMedPubMedCentral
46.
M. Askmyr, H. Agerstam, N. Hansen, S. Gordon, A. Arvanitakis, M. Rissler, G. Juliusson, J. Richter, M. Jaras, T. Fioretos, Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 121, 3709–3713 (2013). doi:10.​1182/​blood-2012-09-458935 CrossRefPubMed
47.
D.E. Berardi, C. Flumian, P.B. Campodonico, A.J. Urtreger, M.I. Diaz Bessone, A.N. Motter, E.D. Bal de Kier Joffe, E.F. Farias, L.B. Todaro, Myoepithelial and luminal breast cancer cells exhibit different responses to all-trans retinoic acid. Cell. Oncol. 38, 289–305 (2015). doi:10.​1007/​s13402-015-0230-z CrossRef
48.
A. Kakizuka, W.H. Miller Jr., K. Umesono, R.P. Warrell Jr., S.R. Frankel, V.V. Murty, E. Dmitrovsky, R.M. Evans, Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66, 663–674 (1991)CrossRefPubMed
49.
P.V. Sanchez, S.T. Glantz, S. Scotland, M.T. Kasner, M. Carroll, Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors. Leukemia 28, 749–760 (2014). doi:10.​1038/​leu.​2013.​202 CrossRefPubMed
50.
51.
H. El Hajj, Z. Dassouki, C. Berthier, E. Raffoux, L. Ades, O. Legrand, R. Hleihel, U. Sahin, N. Tawil, A. Salameh, K. Zibara, N. Darwiche, M. Mohty, H. Dombret, P. Fenaux, H. de The, A. Bazarbachi, Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. Blood 125, 3447–3454 (2015). doi:10.​1182/​blood-2014-11-612416 CrossRefPubMed
52.
X. Zheng, A. Seshire, B. Ruster, G. Bug, T. Beissert, E. Puccetti, D. Hoelzer, R. Henschler, M. Ruthardt, Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica 92, 323–331 (2007)CrossRefPubMed
53.
Y. Jiang, Z.H. Xue, W.Z. Shen, K.M. Du, H. Yan, Y. Yu, Z.G. Peng, M.G. Song, J.H. Tong, Z. Chen, Y. Huang, M. Lubbert, G.Q. Chen, Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha. Leukemia 19, 1239–1247 (2005). doi:10.​1038/​sj.​leu.​2403734 CrossRefPubMed
54.
M. Roth, B. Will, G. Simkin, S. Narayanagari, L. Barreyro, B. Bartholdy, R. Tamari, C.S. Mitsiades, A. Verma, U. Steidl, Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood 120, 386–394 (2012). doi:10.​1182/​blood-2011-12-399667 CrossRefPubMedPubMedCentral
55.
M. Szwed, A. Laroche-Clary, J. Robert, Z. Jozwiak, Efficacy of doxorubicin-transferrin conjugate in apoptosis induction in human leukemia cells through reactive oxygen species generation. Cell. Oncol. 39, 107–118 (2016). doi:10.​1007/​s13402-015-0256-2 CrossRef
56.
J. Liu, X. Wei, Y. Wu, Y. Wang, Y. Qiu, J. Shi, H. Zhou, Z. Lu, M. Shao, L. Yu, L. Tong, Giganteaside D induces ROS-mediated apoptosis in human hepatocellular carcinoma cells through the MAPK pathway. Cell. Oncol. 39, 333–342 (2016). doi:10.​1007/​s13402-016-0273-9 CrossRef
57.
58.
D.J. Goff, A. Court Recart, A. Sadarangani, H.J. Chun, C.L. Barrett, M. Krajewska, H. Leu, J. Low-Marchelli, W. Ma, A.Y. Shih, J. Wei, D. Zhai, I. Geron, M. Pu, L. Bao, R. Chuang, L. Balaian, J. Gotlib, M. Minden, G. Martinelli, J. Rusert, K.H. Dao, K. Shazand, P. Wentworth, K.M. Smith, C.A. Jamieson, S.R. Morris, K. Messer, L.S. Goldstein, T.J. Hudson, M. Marra, K.A. Frazer, M. Pellecchia, J.C. Reed, C.H. Jamieson, A pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 12, 316–328 (2013). doi:10.​1016/​j.​stem.​2012.​12.​011 CrossRefPubMedPubMedCentral
59.
A.S. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M.W. Deininger, B.J. Druker, Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396–409 (2011). doi:10.​1172/​JCI35721 CrossRefPubMed
60.
M. Konopleva, M. Milella, P. Ruvolo, J.C. Watts, M.R. Ricciardi, B. Korchin, T. McQueen, W. Bornmann, T. Tsao, P. Bergamo, D.H. Mak, W. Chen, J. McCubrey, A. Tafuri, M. Andreeff, MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia 26, 778–787 (2012). doi:10.​1038/​leu.​2011.​287 CrossRefPubMed
61.
M. Rahmani, M.M. Aust, E. Attkisson, D.C. Williams Jr., A. Ferreira-Gonzalez, S. Grant, Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 119, 6089–6098 (2012). doi:10.​1182/​blood-2011-09-378141 CrossRefPubMedPubMedCentral
62.
M. Skrtic, S. Sriskanthadevan, B. Jhas, M. Gebbia, X. Wang, Z. Wang, R. Hurren, Y. Jitkova, M. Gronda, N. Maclean, C.K. Lai, Y. Eberhard, J. Bartoszko, P. Spagnuolo, A.C. Rutledge, A. Datti, T. Ketela, J. Moffat, B.H. Robinson, J.H. Cameron, J. Wrana, C.J. Eaves, M.D. Minden, J.C. Wang, J.E. Dick, K. Humphries, C. Nislow, G. Giaever, A.D. Schimmer, Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20, 674–688 (2011). doi:10.​1016/​j.​ccr.​2011.​10.​015 CrossRefPubMedPubMedCentral
63.
64.
K. Goetze, C.G. Fabian, A. Siebers, L. Binz, D. Faber, S. Indraccolo, G. Nardo, U.G. Sattler, W. Mueller-Klieser, Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model system. Cell. Oncol. (Dordr) 38, 377–385 (2015). doi:10.​1007/​s13402-015-0237-5 CrossRef
65.
66.
D. Anastasiou, Y. Yu, W.J. Israelsen, J.K. Jiang, M.B. Boxer, B.S. Hong, W. Tempel, S. Dimov, M. Shen, A. Jha, H. Yang, K.R. Mattaini, C.M. Metallo, B.P. Fiske, K.D. Courtney, S. Malstrom, T.M. Khan, C. Kung, A.P. Skoumbourdis, H. Veith, N. Southall, M.J. Walsh, K.R. Brimacombe, W. Leister, S.Y. Lunt, Z.R. Johnson, K.E. Yen, K. Kunii, S.M. Davidson, H.R. Christofk, C.P. Austin, J. Inglese, M.H. Harris, J.M. Asara, G. Stephanopoulos, F.G. Salituro, S. Jin, L. Dang, D.S. Auld, H.W. Park, L.C. Cantley, C.J. Thomas, M.G. Vander Heiden, Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 8, 839–847 (2012). doi:10.​1038/​nchembio.​1060 CrossRefPubMedPubMedCentral
67.
K.M. Parnell, J.M. Foulks, R.N. Nix, A. Clifford, J. Bullough, B. Luo, A. Senina, D. Vollmer, J. Liu, V. McCarthy, Y. Xu, M. Saunders, X.H. Liu, S. Pearce, K. Wright, M. O’Reilly, M.V. McCullar, K.K. Ho, S.B. Kanner, Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Mol. Cancer Ther. 12, 1453–1460 (2013). doi:10.​1158/​1535-7163.​MCT-13-0026 CrossRefPubMed
68.
T. Hitosugi, S. Kang, M.G. Vander Heiden, T.W. Chung, S. Elf, K. Lythgoe, S. Dong, S. Lonial, X. Wang, G.Z. Chen, J. Xie, T.L. Gu, R.D. Polakiewicz, J.L. Roesel, T.J. Boggon, F.R. Khuri, D.G. Gilliland, L.C. Cantley, J. Kaufman, J. Chen, Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2, ra73 (2009). doi:10.​1126/​scisignal.​2000431 CrossRefPubMedPubMedCentral
69.
E.M. Sturgill, M.L. Guzman, In Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, (San Diego, CA) (2014)
70.
71.
72.
E.D. Lagadinou, A. Sach, K. Callahan, R.M. Rossi, S.J. Neering, M. Minhajuddin, J.M. Ashton, S. Pei, V. Grose, K.M. O’Dwyer, J.L. Liesveld, P.S. Brookes, M.W. Becker, C.T. Jordan, BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329–341 (2013). doi:10.​1016/​j.​stem.​2012.​12.​013 CrossRefPubMedPubMedCentral
73.
C. Craddock, L. Quek, N. Goardon, S. Freeman, S. Siddique, M. Raghavan, A. Aztberger, A. Schuh, D. Grimwade, A. Ivey, P. Virgo, R. Hills, T. McSkeane, J. Arrazi, S. Knapper, C. Brookes, B. Davies, A. Price, K. Wall, M. Griffiths, J. Cavenagh, R. Majeti, I. Weissman, A. Burnett, P. Vyas, Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 27, 1028–1036 (2013). doi:10.​1038/​leu.​2012.​312 CrossRefPubMed
74.
75.
P. Jo, K. Jung, M. Grade, L.C. Conradi, H.A. Wolff, J. Kitz, H. Becker, J. Ruschoff, A. Hartmann, T. Beissbarth, A. Muller-Dornieden, M. Ghadimi, R. Schneider-Stock, J. Gaedcke, CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. Surgery 151, 564–570 (2012). doi:10.​1016/​j.​surg.​2011.​08.​013 CrossRefPubMed
76.
77.
T. Schenk, W.C. Chen, S. Gollner, L. Howell, L. Jin, K. Hebestreit, H.U. Klein, A.C. Popescu, A. Burnett, K. Mills, R.A. Casero Jr., L. Marton, P. Woster, M.D. Minden, M. Dugas, J.C. Wang, J.E. Dick, C. Muller-Tidow, K. Petrie, A. Zelent, Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 18, 605–611 (2012). doi:10.​1038/​nm.​2661 CrossRefPubMedPubMedCentral
78.
S.R. Daigle, E.J. Olhava, C.A. Therkelsen, C.R. Majer, C.J. Sneeringer, J. Song, L.D. Johnston, M.P. Scott, J.J. Smith, Y. Xiao, L. Jin, K.W. Kuntz, R. Chesworth, M.P. Moyer, K.M. Bernt, J.C. Tseng, A.L. Kung, S.A. Armstrong, R.A. Copeland, V.M. Richon, R.M. Pollock, Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53–65 (2011). doi:10.​1016/​j.​ccr.​2011.​06.​009 CrossRefPubMedPubMedCentral
79.
80.
D.P. Mould, A.E. McGonagle, D.H. Wiseman, E.L. Williams, A.M. Jordan, Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date. Med. Res. Rev. 35, 586–618 (2014). doi:10.​1002/​med.​21334 CrossRefPubMed
81.
W. Fiskus, Y. Wang, A. Sreekumar, K.M. Buckley, H. Shi, A. Jillella, C. Ustun, R. Rao, P. Fernandez, J. Chen, R. Balusu, S. Koul, P. Atadja, V.E. Marquez, K.N. Bhalla, Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114, 2733–2743 (2009). doi:10.​1182/​blood-2009-03-213496 CrossRefPubMedPubMedCentral
82.
J. Zhou, C. Bi, L.L. Cheong, S. Mahara, S.C. Liu, K.G. Tay, T.L. Koh, Q. Yu, W.J. Chng, The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 118, 2830–2839 (2011). doi:10.​1182/​blood-2010-07-294827 CrossRefPubMed
83.
A. Chaturvedi, M.M. Araujo Cruz, N. Jyotsana, A. Sharma, H. Yun, K. Gorlich, M. Wichmann, A. Schwarzer, M. Preller, F. Thol, J. Meyer, R. Haemmerle, E.A. Struys, E.E. Jansen, U. Modlich, Z. Li, L.M. Sly, R. Geffers, R. Lindner, D.J. Manstein, U. Lehmann, J. Krauter, A. Ganser, M. Heuser, Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 122, 2877–2887 (2013). doi:10.​1182/​blood-2013-03-491571 CrossRefPubMed
84.
M.E. Figueroa, S. Lugthart, Y. Li, C. Erpelinck-Verschueren, X. Deng, P.J. Christos, E. Schifano, J. Booth, W. van Putten, L. Skrabanek, F. Campagne, M. Mazumdar, J.M. Greally, P.J. Valk, B. Lowenberg, R. Delwel, A. Melnick, DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13–27 (2010). doi:10.​1016/​j.​ccr.​2009.​11.​020 CrossRefPubMedPubMedCentral
85.
86.
C. Frelin, V. Imbert, E. Griessinger, A.C. Peyron, N. Rochet, P. Philip, C. Dageville, A. Sirvent, M. Hummelsberger, E. Berard, M. Dreano, N. Sirvent, J.F. Peyron, Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 105, 804–811 (2005). doi:10.​1182/​blood-2004-04-1463 CrossRefPubMed
87.
K. Vazquez-Santillan, J. Melendez-Zajgla, L. Jimenez-Hernandez, G. Martinez-Ruiz, V. Maldonado, NF-kappaB signaling in cancer stem cells: a promising therapeutic target? Cell. Oncol. 38, 327–339 (2015). doi:10.​1007/​s13402-015-0236-6 CrossRef
88.
M.L. Guzman, S.J. Neering, D. Upchurch, B. Grimes, D.S. Howard, D.A. Rizzieri, S.M. Luger, C.T. Jordan, Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98, 2301–2307 (2001)CrossRefPubMed
89.
Y. Kagoya, A. Yoshimi, K. Kataoka, M. Nakagawa, K. Kumano, S. Arai, H. Kobayashi, T. Saito, Y. Iwakura, M. Kurokawa, Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell capacity. J. Clin. Invest. 124, 528–542 (2014). doi:10.​1172/​JCI68101 CrossRefPubMedPubMedCentral
90.
91.
P. Diamanti, C.V. Cox, J.P. Moppett, A. Blair, Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia. Blood 121, 1384–1393 (2013). doi:10.​1182/​blood-2012-08-448852 CrossRefPubMed
92.
M.L. Guzman, R.M. Rossi, S. Neelakantan, X. Li, C.A. Corbett, D.C. Hassane, M.W. Becker, J.M. Bennett, E. Sullivan, J.L. Lachowicz, A. Vaughan, C.J. Sweeney, W. Matthews, M. Carroll, J.L. Liesveld, P.A. Crooks, C.T. Jordan, An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110, 4427–4435 (2007). doi:10.​1182/​blood-2007-05-090621 CrossRefPubMedPubMedCentral
93.
94.
M.L. Guzman, N. Yang, K.K. Sharma, M. Balys, C.A. Corbett, C.T. Jordan, M.W. Becker, U. Steidl, O. Abdel-Wahab, R.L. Levine, G. Marcucci, G.J. Roboz, D.C. Hassane, Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Mol. Cancer Ther. 13, 1979–1990 (2014). doi:10.​1158/​1535-7163.​MCT-13-0963 CrossRefPubMedPubMedCentral
95.
N. Lounnas, C. Frelin, N. Gonthier, P. Colosetti, A. Sirvent, J.P. Cassuto, F. Berthier, N. Sirvent, P. Rousselot, M. Dreano, J.F. Peyron, V. Imbert, NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants. Int. J. Cancer 125, 308–317 (2009). doi:10.​1002/​ijc.​24294 CrossRefPubMed
96.
97.
T. Skorski, P. Kanakaraj, M. Nieborowska-Skorska, M.Z. Ratajczak, S.C. Wen, G. Zon, A.M. Gewirtz, B. Perussia, B. Calabretta, Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86, 726–736 (1995)PubMed
98.
C. Billottet, V.L. Grandage, R.E. Gale, A. Quattropani, C. Rommel, B. Vanhaesebroeck, A. Khwaja, A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 25, 6648–6659 (2006). doi:10.​1038/​sj.​onc.​1209670 CrossRefPubMed
99.
A.M. Martelli, C. Evangelisti, F. Chiarini, J.A. McCubrey, The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 1, 89–103 (2010)CrossRefPubMedPubMedCentral
100.
P.L. Tazzari, A. Cappellini, F. Ricci, C. Evangelisti, V. Papa, T. Grafone, G. Martinelli, R. Conte, L. Cocco, J.A. McCubrey, A.M. Martelli, Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21, 427–438 (2007). doi:10.​1038/​sj.​leu.​2404523 CrossRefPubMed
101.
102.
V. Papa, P.L. Tazzari, F. Chiarini, A. Cappellini, F. Ricci, A.M. Billi, C. Evangelisti, E. Ottaviani, G. Martinelli, N. Testoni, J.A. McCubrey, A.M. Martelli, Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 22, 147–160 (2008). doi:10.​1038/​sj.​leu.​2404980 CrossRefPubMed
103.
104.
C. Recher, O. Beyne-Rauzy, C. Demur, G. Chicanne, C. Dos Santos, V.M. Mas, D. Benzaquen, G. Laurent, F. Huguet, B. Payrastre, Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105, 2527–2534 (2005). doi:10.​1182/​blood-2004-06-2494 CrossRefPubMed
105.
106.
F. Chiarini, A. Lonetti, G. Teti, E. Orsini, D. Bressanin, A. Cappellini, F. Ricci, P.L. Tazzari, A. Ognibene, M. Falconi, P. Pagliaro, I. Iacobucci, G. Martinelli, S. Amadori, J.A. McCubrey, A.M. Martelli, A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget 3, 1615–1628 (2012)CrossRefPubMedPubMedCentral
107.
D.C. Hassane, S. Sen, M. Minhajuddin, R.M. Rossi, C.A. Corbett, M. Balys, L. Wei, P.A. Crooks, M.L. Guzman, C.T. Jordan, Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood 116, 5983–5990 (2010). doi:10.​1182/​blood-2010-04-278044 CrossRefPubMed
108.
K. Meja, C. Stengel, R. Sellar, D. Huszar, B.R. Davies, R.E. Gale, D.C. Linch, A. Khwaja, PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. Br. J. Haematol. 167, 69–79 (2014). doi:10.​1111/​bjh.​13013 CrossRefPubMed
109.
F. Pellicano, M.T. Scott, G.V. Helgason, L.E. Hopcroft, E.K. Allan, M. Aspinall-O’Dea, M. Copland, A. Pierce, B.J. Huntly, A.D. Whetton, T.L. Holyoake, The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem Cells 32, 2324–2337 (2014). doi:10.​1002/​stem.​1748 CrossRefPubMedPubMedCentral
110.
N. Chapuis, J. Tamburini, A.S. Green, C. Vignon, V. Bardet, A. Neyret, M. Pannetier, L. Willems, S. Park, A. Macone, S.M. Maira, N. Ifrah, F. Dreyfus, O. Herault, C. Lacombe, P. Mayeux, D. Bouscary, Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin. Cancer Res. 16, 5424–5435 (2010). doi:10.​1158/​1078-0432.​CCR-10-1102 CrossRefPubMed
111.
X. Ding, F. Li, J. McKnight, C. Schmidt, K. Strooisma, H. Shimizu, K. Faber, J.A. Ware, B. Dean, A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. J. Pharm. Biomed. Anal. 100, 150–156 (2014). doi:10.​1016/​j.​jpba.​2014.​08.​001 CrossRefPubMed
112.
P. Yu, A.D. Laird, X. Du, J. Wu, K.A. Won, K. Yamaguchi, P.P. Hsu, F. Qian, C.T. Jaeger, W. Zhang, C.A. Buhr, P. Shen, W. Abulafia, J. Chen, J. Young, A. Plonowski, F.M. Yakes, F. Chu, M. Lee, F. Bentzien, S.T. Lam, S. Dale, D.J. Matthews, P. Lamb, P. Foster, Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol. Cancer Ther. 13, 1078–1091 (2014). doi:10.​1158/​1535-7163.​MCT-13-0709 CrossRefPubMed
113.
114.
K. Ito, A. Hirao, F. Arai, K. Takubo, S. Matsuoka, K. Miyamoto, M. Ohmura, K. Naka, K. Hosokawa, Y. Ikeda, T. Suda, Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat. Med. 12, 446–451 (2006). doi:10.​1038/​nm1388 CrossRefPubMed
115.
116.
M. Nieborowska-Skorska, P.K. Kopinski, R. Ray, G. Hoser, D. Ngaba, S. Flis, K. Cramer, M.M. Reddy, M. Koptyra, T. Penserga, E. Glodkowska-Mrowka, E. Bolton, T.L. Holyoake, C.J. Eaves, S. Cerny-Reiterer, P. Valent, A. Hochhaus, T.P. Hughes, H. van der Kuip, M. Sattler, W. Wiktor-Jedrzejczak, C. Richardson, A. Dorrance, T. Stoklosa, D.A. Williams, T. Skorski, Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 119, 4253–4263 (2012). doi:10.​1182/​blood-2011-10-385658 CrossRefPubMedPubMedCentral
117.
S. Pei, M. Minhajuddin, K.P. Callahan, M. Balys, J.M. Ashton, S.J. Neering, E.D. Lagadinou, C. Corbett, H. Ye, J.L. Liesveld, K.M. O’Dwyer, Z. Li, L. Shi, P. Greninger, J. Settleman, C. Benes, F.K. Hagen, J. Munger, P.A. Crooks, M.W. Becker, C.T. Jordan, Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J. Biol. Chem. 288, 33542–33558 (2013). doi:10.​1074/​jbc.​M113.​511170 CrossRefPubMedPubMedCentral
118.
X. Chen, X. Shi, C. Zhao, X. Li, X. Lan, S. Liu, H. Huang, N. Liu, S. Liao, D. Zang, W. Song, Q. Liu, B.Z. Carter, Q.P. Dou, X. Wang, J. Liu, Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. Oncotarget 5, 9118–9132 (2014)CrossRefPubMedPubMedCentral
119.
120.
K. Moulick, J.H. Ahn, H. Zong, A. Rodina, L. Cerchietti, E.M. Gomes DaGama, E. Caldas-Lopes, K. Beebe, F. Perna, K. Hatzi, L.P. Vu, X. Zhao, D. Zatorska, T. Taldone, P. Smith-Jones, M. Alpaugh, S.S. Gross, N. Pillarsetty, T. Ku, J.S. Lewis, S.M. Larson, R. Levine, H. Erdjument-Bromage, M.L. Guzman, S.D. Nimer, A. Melnick, L. Neckers, G. Chiosis, Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat. Chem. Biol. 7, 818–826 (2011). doi:10.​1038/​nchembio.​670 CrossRefPubMedPubMedCentral
121.
122.
H. Reikvam, K.J. Hatfield, E. Ersvaer, R. Hovland, J. Skavland, B.T. Gjertsen, K. Petersen, O. Bruserud, Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention. Br. J. Haematol. 156, 468–480 (2012). doi:10.​1111/​j.​1365-2141.​2011.​08960.​x CrossRefPubMed
123.
124.
W. Yu, Q. Rao, M. Wang, Z. Tian, D. Lin, X. Liu, J. Wang, The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level. Leuk. Res. 30, 575–582 (2006). doi:10.​1016/​j.​leukres.​2005.​08.​028
125.
J.E. Lancet, I. Gojo, M. Burton, M. Quinn, S.M. Tighe, K. Kersey, Z. Zhong, M.X. Albitar, K. Bhalla, A.L. Hannah, M.R. Baer, Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 24, 699–705 (2010). doi:10.​1038/​leu.​2009.​292 CrossRefPubMed
126.
C. Gallerne, A. Prola, C. Lemaire, Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2. Biochim. Biophys. Acta 1833, 1356–1366 (2013). doi:10.​1016/​j.​bbamcr.​2013.​02.​014 CrossRefPubMed
127.
S.R. Ambati, E.C. Lopes, K. Kosugi, U. Mony, A. Zehir, S.K. Shah, T. Taldone, A.L. Moreira, P.A. Meyers, G. Chiosis, M.A. Moore, Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma. Mol. Oncol. 8, 323–336 (2014). doi:10.​1016/​j.​molonc.​2013.​12.​005 CrossRefPubMed
128.
H. Zong, A. Gozman, E. Caldas-Lopes, T. Taldone, E. Sturgill, S. Brennan, S.O. Ochiana, E.M. Gomes-DaGama, S. Sen, A. Rodina, J. Koren 3rd, M.W. Becker, C.M. Rudin, A. Melnick, R.L. Levine, G.J. Roboz, S.D. Nimer, G. Chiosis, M.L. Guzman, A hyperactive signalosome in acute myeloid leukemia drives addiction to a tumor-specific Hsp90 species. Cell Rep. 13, 2159–2173 (2015). doi:10.​1016/​j.​celrep.​2015.​10.​073 CrossRefPubMedPubMedCentral
129.
C. Hurtz, K. Hatzi, L. Cerchietti, M. Braig, E. Park, Y.M. Kim, S. Herzog, P. Ramezani-Rad, H. Jumaa, M.C. Muller, W.K. Hofmann, A. Hochhaus, B.H. Ye, A. Agarwal, B.J. Druker, N.P. Shah, A.M. Melnick, M. Muschen, BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J. Exp. Med. 208, 2163–2174 (2011). doi:10.​1084/​jem.​20110304 CrossRefPubMedPubMedCentral
130.
J.M. Polo, T. Dell’Oso, S.M. Ranuncolo, L. Cerchietti, D. Beck, G.F. Da Silva, G.G. Prive, J.D. Licht, A. Melnick, Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat. Med. 10, 1329–1335 (2004). doi:10.​1038/​nm1134 CrossRefPubMed
131.
C. Duy, J.J. Yu, R. Nahar, S. Swaminathan, S.M. Kweon, J.M. Polo, E. Valls, L. Klemm, S. Shojaee, L. Cerchietti, W. Schuh, H.M. Jack, C. Hurtz, P. Ramezani-Rad, S. Herzog, H. Jumaa, H.P. Koeffler, I.M. de Alboran, A.M. Melnick, B.H. Ye, M. Muschen, BCL6 is critical for the development of a diverse primary B cell repertoire. J. Exp. Med. 207, 1209–1221 (2010). doi:10.​1084/​jem.​20091299 CrossRefPubMedPubMedCentral
132.
133.
A.E. Abrahamsson, I. Geron, J. Gotlib, K.H. Dao, C.F. Barroga, I.G. Newton, F.J. Giles, J. Durocher, R.S. Creusot, M. Karimi, C. Jones, J.L. Zehnder, A. Keating, R.S. Negrin, I.L. Weissman, C.H. Jamieson, Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc. Natl. Acad. Sci. U. S. A. 106, 3925–3929 (2009). doi:10.​1073/​pnas.​0900189106 CrossRefPubMedPubMedCentral
134.
135.
J.P. Radich, H. Dai, M. Mao, V. Oehler, J. Schelter, B. Druker, C. Sawyers, N. Shah, W. Stock, C.L. Willman, S. Friend, P.S. Linsley, Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A. 103, 2794–2799 (2006). doi:10.​1073/​pnas.​0510423103 CrossRefPubMedPubMedCentral
136.
137.
138.
139.
140.
S. Song, T. Christova, S. Perusini, S. Alizadeh, R.Y. Bao, B.W. Miller, R. Hurren, Y. Jitkova, M. Gronda, M. Isaac, B. Joseph, R. Subramaniam, A. Aman, A. Chau, D.E. Hogge, S.J. Weir, J. Kasper, A.D. Schimmer, R. Al-awar, J.L. Wrana, L. Attisano, Wnt inhibitor screen reveals iron dependence of beta-catenin signaling in cancers. Cancer Res. 71, 7628–7639 (2011). doi:10.​1158/​0008-5472.​CAN-11-2745 CrossRefPubMed
141.
142.
143.
F. Damm, B. Markus, F. Thol, M. Morgan, G. Gohring, B. Schlegelberger, J. Krauter, M. Heuser, O.A. Bernard, A. Ganser, TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns. Genes Chromosomes Cancer 53, 824–832 (2014). doi:10.​1002/​gcc.​22191 CrossRefPubMed
144.
C. Lobry, P. Ntziachristos, D. Ndiaye-Lobry, P. Oh, L. Cimmino, N. Zhu, E. Araldi, W. Hu, J. Freund, O. Abdel-Wahab, S. Ibrahim, D. Skokos, S.A. Armstrong, R.L. Levine, C.Y. Park, I. Aifantis, Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J. Exp. Med. 210, 301–319 (2013). doi:10.​1084/​jem.​20121484 CrossRefPubMedPubMedCentral
145.
C. Dierks, R. Beigi, G.R. Guo, K. Zirlik, M.R. Stegert, P. Manley, C. Trussell, A. Schmitt-Graeff, K. Landwerlin, H. Veelken, M. Warmuth, Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14, 238–249 (2008). doi:10.​1016/​j.​ccr.​2008.​08.​003 CrossRefPubMed
146.
147.
L. Jin, Y. Tabe, S. Konoplev, Y. Xu, C.E. Leysath, H. Lu, S. Kimura, A. Ohsaka, M.B. Rios, L. Calvert, H. Kantarjian, M. Andreeff, M. Konopleva, CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol. Cancer Ther. 7, 48–58 (2008). doi:10.​1158/​1535-7163.​MCT-07-0042 CrossRefPubMed
148.
L. Brault, A. Rovo, S. Decker, C. Dierks, A. Tzankov, J. Schwaller, CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia. Leukemia 28, 566–576 (2014). doi:10.​1038/​leu.​2013.​201 CrossRefPubMed
149.
E. Weisberg, A.K. Azab, P.W. Manley, A.L. Kung, A.L. Christie, R. Bronson, I.M. Ghobrial, J.D. Griffin, Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 26, 985–990 (2012). doi:10.​1038/​leu.​2011.​360 CrossRefPubMed
150.
S. Tavor, I. Petit, S. Porozov, A. Avigdor, A. Dar, L. Leider-Trejo, N. Shemtov, V. Deutsch, E. Naparstek, A. Nagler, T. Lapidot, CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 64, 2817–2824 (2004)CrossRefPubMed
151.
152.
M. Shahjahani, J. Mohammadiasl, F. Noroozi, M. Seghatoleslami, S. Shahrabi, F. Saba, N. Saki, Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis. Cell. Oncol. 38, 93–109 (2015). doi:10.​1007/​s13402-014-0215-3 CrossRef
153.
A. Chávez-González, S. Avilés-Vázquez, D. Moreno-Lorenzana, H. Mayani, in Stem cell biology in normal life and diseases, ed. by K. Alimoghaddam (InTech, 2013)
154.
155.
R. Bhatia, M. Holtz, N. Niu, R. Gray, D.S. Snyder, C.L. Sawyers, D.A. Arber, M.L. Slovak, S.J. Forman, Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701–4707 (2003). doi:10.​1182/​blood-2002-09-2780 CrossRefPubMed
156.
M. Copland, A. Hamilton, L.J. Elrick, J.W. Baird, E.K. Allan, N. Jordanides, M. Barow, J.C. Mountford, T.L. Holyoake, Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107, 4532–4539 (2006). doi:10.​1182/​blood-2005-07-2947 CrossRefPubMed
157.
H.G. Jorgensen, E.K. Allan, N.E. Jordanides, J.C. Mountford, T.L. Holyoake, Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109, 4016–4019 (2007). doi:10.​1182/​blood-2006-11-057521 CrossRefPubMed
158.
A. Hamilton, G.V. Helgason, M. Schemionek, B. Zhang, S. Myssina, E.K. Allan, F.E. Nicolini, C. Muller-Tidow, R. Bhatia, V.G. Brunton, S. Koschmieder, T.L. Holyoake, Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119, 1501–1510 (2012). doi:10.​1182/​blood-2010-12-326843 CrossRefPubMedPubMedCentral
159.
160.
J.H. Black, J.A. McCubrey, M.C. Willingham, J. Ramage, D.E. Hogge, A.E. Frankel, Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice. Leukemia 17, 155–159 (2003). doi:10.​1038/​sj.​leu.​2402744 CrossRefPubMed
161.
Metadata
Title
Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer
Authors
Antonieta Chavez-Gonzalez
Babak Bakhshinejad
Katayoon Pakravan
Monica L. Guzman
Sadegh Babashah
Publication date
01-02-2017
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 1/2017
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-016-0297-1

Other articles of this Issue 1/2017

Cellular Oncology 1/2017 Go to the issue

Original Paper

miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma

Original Paper

Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma

Original Paper

Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia

Original Paper

Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine

Short Communication

MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report

Original Paper

Collective cell migration of thyroid carcinoma cells: a beneficial ability to override unfavourable substrates
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits